Medacta Group Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Medacta Group ha aumentado sus beneficios a una tasa media anual de 14%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 7.6% anual. Los ingresos han ido creciendo a una tasa media de 13% al año. La rentabilidad financiera de Medacta Group es de 14.4%, y sus márgenes netos son de 9.3%.

Información clave

14.0%

Tasa de crecimiento de los beneficios

17.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	11.1%
Tasa de crecimiento de los ingresos	13.0%
Rentabilidad financiera	14.4%
Margen neto	9.3%
Próxima actualización de resultados	26 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Medacta Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SWX:MOVE Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	511	47	252	19
30 Sep 23	496	49	245	18
30 Jun 23	481	50	237	17
31 Mar 23	459	48	228	16
31 Dec 22	437	46	220	15
30 Sep 22	417	47	212	14
30 Jun 22	397	47	203	14
31 Mar 22	380	49	193	12
31 Dec 21	363	52	182	11
30 Sep 21	354	54	173	10
30 Jun 21	345	57	164	8
31 Mar 21	324	47	160	7
31 Dec 20	302	37	155	7
30 Sep 20	298	24	166	7
30 Jun 20	294	10	177	7
31 Mar 20	302	11	177	8
31 Dec 19	311	12	176	8
30 Sep 19	301	22	162	6
30 Jun 19	291	33	147	5
31 Mar 19	282	39	143	5
31 Dec 18	273	46	139	4
31 Dec 17	245	33	129	3
31 Dec 16	219	39	113	3

Ingresos de calidad: MOVE tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(9.3%) de MOVE son inferiores a los del año pasado (10.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de MOVE han crecido un 14% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de MOVE en el último año (2.4%) está por debajo de su media de 5 años (14% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de MOVE en el último año (2.4%) superó al de la industria Medical Equipment -7.1%.

Medacta Group Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Recent updates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

Medacta Announces First U.S. Surgery with the New M.U.S.T. Lt System in Minimally Invasive Spine Surgery

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Full year 2020 earnings released: EPS €1.86 (vs €0.59 in FY 2019)

Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Medacta Adds the MyHip Planner and the MyHip Verifier Tools to Its Medicine Solutions for Hip Replacement

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

New 90-day high: CHF103

Medacta Group SA to Report Q2, 2021 Final Results on Sep 10, 2021

New 90-day high: CHF91.60

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Medacta Group SA, Annual General Meeting, May 25, 2021

Medacta Announces Successful Completion of the First TKA Surgery in the U.S. with NextAR Augmented Reality-Based Surgical Platform

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

New 90-day low: CHF82.40

Medacta Expands Its Knee Offerings with New SensiTiN System with Low Metal Ion Release

Desglose de ingresos y gastos
Beta